Results 251 to 260 of about 5,147,794 (406)

Assessment and Mitigation of CRISPR‐Cas9‐Induced Nontargeted Translocations

Advanced Science, EarlyView.
Various inverted repeat elements are dispersed throughout genomes. This study reveals that these elements can cause significant chromosomal rearrangements when CRISPR editing occurs in their proximity. The risk can be mitigated by incorporating inverted repeat‐homologous segments into the CRISPR system, which represents a promising strategy for ...
Zhiyang Hou, Qiyi Yi, Mengying Wu, Lijun Wu, Fanghua Li, Ting Wang, Po Bian   +6 more
wiley   +1 more source

Proton Radiation and TNF-α/Bax Gene Therapy for Orthotopic C6 Brain Tumor in Wistar Rats [PDF]

, 2004
Daila S. Gridley, Glen M. Miller, Xian Luo, Jeffrey D. Cao, Tatyana M. Timiryasova, István Fodor, James M. Slater   +6 more
openalex   +1 more source

Envisioning an Italian Head and Neck Proton Therapy Model-Based Selection: Challenge and Opportunity. [PDF]

Int J Part Ther
Fontana G, Pepa M, Camarda AM, Strikchani M, Meregaglia M, Vai A, Mirandola A, Vischioni B, Pella A, Baroni G, Jereczek-Fossa BA, Scorsetti M, Cianchetti M, D'Angelo E, Bonomo P, Krengli M, Orlandi E.   +16 more
europepmc   +1 more source

Proton Beam Therapy [PDF]

, 2011
openaire   +2 more sources

Neuraminidase 1 Exacerbated Glycolytic Dysregulation and Cardiotoxicity by Destabilizing SIRT1 through Interactions with NRF2 and HIF1α

Advanced Science, EarlyView.
NEU1, a key regulator of glycolysis, is markedly upregulated following DOX treatment. This upregulation is attributed to HIF1α’s transcriptional repression, requiring intricate interactions with NRF2. Increased NEU1 facilitates SIRT1 lysosomal degradation, contributing to aberrant glycolytic phenotype and cardiac damage.
Ting Gao, Yufeng Tang, Tao Zeng, Jie Wang, Xiaohui Zhang, Qingbo Liu, Xun Guan, Xinyu Tang, Guangping Lu, Jiahao Li, Mingrui Liu, Dongmei Zhang, Sixuan Lv, Junlian Gu   +13 more
wiley   +1 more source

Application of Photon-Derived Worst-Case Robustness Criteria to Proton Therapy Planning. [PDF]

Int J Part Ther
Siwakoti K, Dalton AP, Maas JA, McDonald AM, Marcrom SR, Cardan RA, Harms J, Fiveash JB, Kole AJ.   +8 more
europepmc   +1 more source

High Health Care Spending and Developing Technology: Proton Beam Therapy [PDF]

, 2020
Han, Yoojeong Jaye
core   +1 more source

Development of Carbon‐11 Labeled Pyrimidine Derivatives as Novel Positron Emission Tomography (PET) Agents Enabling Brain Sigma‐1 Receptor Imaging

Advanced Science, EarlyView.
Novel carbon‐11 labeled pyrimidine derivatives are developed as PET imaging probes for visualizing sigma‐1 receptors in the brain. [11C]CNY‐01 demonstrates superior brain uptake and binding specificity in both rodents and non‐human primates. The study reveals decreased sigma‐1 receptor expression in Alzheimer's disease, offering a promising tool for ...
Ping Bai, Ashley Gomm, Chi‐Hyeon Yoo, Prasenjit Mondal, Fleur Marie Lobo, Hui Meng, Yanting Zhou, Weiyao Xie, Hsiao‐Ying Wey, Rudolph E. Tanzi, Can Zhang, Changning Wang, Yu Lan   +12 more
wiley   +1 more source

Management of uninvestigated dyspepsia: A randomized, double-blind, placebo-controlled trial of proton pump inhibitor therapy

, 2001
Linda Rabeneck, Julianne Souchek, Kimberly Wristers, Terri Menke, Naomi R. Wray, Eunice Ambriz, Iris W. Huang   +6 more
openalex   +1 more source

Preliminary result of proton beam therapy for malignancies of the nasal cavity and paranasal sinus-with special reference to adverse effects on optic pathways [PDF]

, 2004
Hideki Nishimura, Takashi Ogino, Mitsuhiko Kawashima, Satoshi Ishikura, Keiji Nihei, Masakatsu Onozawa, Satoko Arahira, Shoichi Katsuta, Teiji Nishio, Munefumi Shimbo   +9 more
openalex   +1 more source